Authors

Latest:

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.

Michael Ulm, MD

Latest:

Dr. Ulm on Trial for Postoperative Pain Management in Gynecological Cancer

Michael Ulm, MD, fellow, University of Tennessee Health Science Center, West Cancer Center, discusses the rationale and results of a trial for postoperative pain management in gynecological cancer.

Michael Untch, MD, Helios Klinikum Berlin-Buch

Michael Untch, MD, PhD

Latest:

Dr. Untch on the Expanding Use of Biosimilars

Michael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.

Michael Van Scoy-Mosher, MD

Latest:

Protect Yourself From Malpractice Claims

Compared with other specialists, medical oncologists are not often the target of malpractice litigation. Even so, they still get sued.

Michael Wang, MD

Latest:

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL).

Michael Wang, MD, The University of Texas MD Anderson Cancer Center

Michel Sadelain, MD, PhD,

Latest:

Dr. Sadelain on CAR T-Cell Therapies

Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.

Michel Velez, MD

Latest:

Dr. Velez on Managing Neratinib-Associated Diarrhea in HER2+ Breast Cancer

Michel Velez, MD, medical oncologist at Holy Cross Hospital, discusses the management of neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer.

Michel Vulfovich, MD

Latest:

Dr. Vulfovich on Molecular Testing in Colorectal Cancer

Michel Vulfovich, MD, discusses molecular testing in colorectal cancer.

Michele Cavo, MD

Latest:

Dr. Michele Cavo on ASCT Role in Novel-Agent Era of Multiple Myeloma

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses the role of upfront autologous stem cell transplantation (ASCT) in multiple myeloma.

Michele L. Donato, MD

Latest:

Dr. Donato Discusses the National Marrow Donor Program

Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center (JTCC), provides an overview of the National Marrow Donor Program (NMDP).

Michelle A. Fanale

Latest:

Dr. Fanale on Clinical Trials for T-Cell Lymphoma

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

Michelle A. Fanale, MD

Latest:

Dr. Fanale on Challenges Facing Treatments in T-Cell Lymphoma

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

Michelle Berke

Michelle E. Melisko, MD

Latest:

Dr. Melisko Reflects on Findings From the MINDACT Trial in Breast Cancer

Michelle E. Melisko, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, reflects on the findings from the MINDACT trial in breast cancer.

Michelle Frances Barrord, BS

Latest:

Adjuvant Radiotherapy in Low-Risk Breast Cancer Patients: Review and Clinical Implications

Over the past several decades, breast-conserving therapy has emerged as the standard of care in the management of early-stage breast cancer.

Michelle Krogsgaard, PhD

Latest:

Dr Krogsgaard on Phosphorylated Neoantigen Targets for Anticancer Vaccine Development

Michelle Krogsgaard, PhD, discusses the identification and potentially utility of phosphorylated neoantigen targets for anticancer vaccine development.

Michelle M. Boisen, MD

Latest:

Dr. Boisen on Scoring System for Optimal Debulking in Ovarian Cancer

Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.

Michelle Shayne, MD

Latest:

Introducing Humanities Into the Oncology Curriculum

It seems that every year, the list of Accreditation Council for Graduate Medical Education (ACGME) requirements grows longer and more bewildering.